Healthpeak Properties, Inc. (DOC)

Earnings Preview | Q2 2026 Results | Reporting: August 4, 2026 (After Market Close) | Conference Call: August 5, 2026 at 10:00 AM ET | Prepared: August 3, 2026

Earnings Preview

Key Takeaway: The setup into Q2 is modestly constructive — consensus is a manageable bar at $0.44 Core FFO/share (vs. $0.45 actual in Q1), and the biggest swing factor is whether lab leasing momentum and occupancy trajectory can sustain the positive tone management struck in May.

Heading into Q2 2026 earnings, the bar for Healthpeak is achievable: consensus Core FFO sits at ~$0.44/share, roughly in line with management's guided run-rate of ~$0.43 ± $0.01, and the company has a track record of modest beats. Management's tone on the Q1 call was notably upbeat — CEO Scott Brinker described the lab business as having "massive upside" as the pendulum swings in their favor, and April was cited as the most active month for biotech equity issuance since early 2021, providing a constructive demand backdrop. Estimate revisions have been broadly stable since the Q1 print, with Core FFO consensus for FY2026 ticking up slightly to ~$1.75/share from ~$1.73 at the post-Q1 baseline, suggesting the street is incrementally more confident. The stock has outperformed meaningfully since Q1 earnings — up ~12% vs. ~11% for IYH and ~2% for the S&P 500 — implying some beat expectation is already priced in, which raises the bar for a positive reaction. The key wildcard is lab leasing execution and occupancy trajectory: with ~355,000 sq ft under LOI as of Q1 and management guiding for at least 100 bps of year-end occupancy improvement, any slippage in conversion or new vacates beyond the known ~50,000 sq ft could reset the recovery narrative and pressure the stock despite an in-line print.

KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar heading into Q2 — Core FFO at $0.44/share is essentially in line with management's guided run-rate. Lab same-store NOI growth (consensus: -5.7%) is the bigger swing factor; any improvement vs. the -7.2% Q1 actual would be a positive signal for the recovery narrative.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of latest available. Core FFO is the primary earnings metric for DOC; Adjusted FFO reflects additional non-cash adjustments. Senior Housing same-store NOI consensus of +17.0% sits above the top of management's +8%–+12% FY guidance range, reflecting the strong Q1 outperformance (+13.8%) and Janus Living momentum.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Pattern: DOC has beaten Core FFO consensus in all 8 of the last 8 quarters, typically by 1–4%; Lab same-store NOI has been more volatile — beating in 5 of 8 quarters but missing badly in Q3 2025 and Q1 2026 as occupancy losses accelerated, making it the key swing factor for Q2.

Source: Visible Alpha Consensus and Actuals Data.

Guidance & Commentary Evolution

Key Takeaway: Management raised FY2026 FFO guidance at Q1 earnings (May 6) to $1.71–$1.75 from the original $1.70–$1.74, supported by the $100M buyback at >10% FFO yield. Tone has shifted meaningfully more confident since Q4 2025 — lab recovery language has escalated from cautious to outright bullish, and senior housing is tracking well above initial guidance.

Guidance vs. Estimate Revision Tracker

Key Takeaway: Core FFO estimates for Q2 2026 and FY2026 have drifted modestly higher since the Q1 print, reflecting the buyback accretion and senior housing outperformance. Lab same-store NOI estimates have improved slightly for FY2026 (from -6.3% to -4.9%), suggesting the street is beginning to price in the recovery narrative — a positive setup if Q2 lab data confirms the trend.

Source: Visible Alpha Consensus and Actuals Data. Post-Q1 baseline uses consensus as of May 13, 2026 (5 trading days post-earnings). The most notable revision trend is in Senior Housing, where the street has dramatically re-rated the segment following the Janus Living IPO and Q1 outperformance — consensus at +17% is well above the +8%–+12% FY guidance range, suggesting management guidance is conservative.

Stock Performance

Key Takeaway: DOC has outperformed both the healthcare sector ETF (IYH) and the S&P 500 since Q1 2026 earnings, up ~12% vs. ~11% for IYH and ~2% for SPY — driven by a combination of the Janus Living IPO re-rating, the Blackstone JV recap validating outpatient asset values, and improving lab sentiment. The outperformance is sentiment/multiple-driven rather than estimate-driven, which raises the bar for a positive reaction on Q2 results.

DOC vs. IYH (iShares U.S. Healthcare ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (May 6, 2026). Source: Stock Price Data.

DOC closed at $21.84 on July 31, 2026, up approximately 12.0% from the Q1 earnings date close of $19.50. IYH gained ~11.2% over the same period, while SPY gained ~1.8%. The stock's outperformance vs. IYH was driven by three catalysts: (1) the Janus Living IPO in March, which unlocked a valuation premium for the senior housing portfolio; (2) the Blackstone JV recap in March at a 6.1% cap rate, validating outpatient asset values at a ~200 bps premium to the implied stock price; and (3) improving lab market sentiment as biotech equity issuance surged in April. The Morgan Stanley downgrade on June 11 (Overweight → Equal-Weight, PT raised to $22) created a brief pause but did not derail the rally, suggesting the market is looking through near-term lab headwinds. Sector ETF used: IYH (iShares U.S. Healthcare ETF), which includes diversified healthcare REITs and is the most appropriate benchmark for DOC's multi-segment healthcare real estate portfolio.

Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peers reporting Q2 2026 results in late July paint a broadly constructive picture for DOC's two largest segments: outpatient medical fundamentals are strong (HR: +5.1% SS NOI, WELL: +2–3% MOB guide), and senior housing demand remains exceptional (WELL: 15th consecutive quarter of >20% SHOP NOI growth; VTR: raised FY investment guidance to $4.5B). Lab/life science read-throughs are limited as neither WELL nor VTR has meaningful lab exposure, but the broader biotech capital-raising environment (April: most active month since early 2021) is a positive leading indicator for DOC's lab leasing pipeline.

Welltower (WELL) — Q2 2026 Earnings (Reported July 28, 2026)

Read-Through Relevance: WELL is the largest healthcare REIT and a direct peer in both outpatient medical and senior housing. Its Q2 results are the most important read-through for DOC.

• Outpatient Medical (MOB) — Positive Read-Through for DOC: WELL's updated FY2026 outlook assumes outpatient medical same-store NOI growth of 2–3%, consistent with DOC's own guidance range. WELL noted it executed a "massive portfolio rotation" away from outpatient medical into senior housing, but the segment still delivered solid fundamentals. This validates DOC's outpatient guidance and suggests the segment is performing in line with expectations sector-wide.
• Senior Housing (SHOP) — Very Positive Read-Through for DOC: WELL reported its 15th consecutive quarter of SHOP NOI growth exceeding 20%, with total portfolio same-store NOI up 15.5% YoY — the second highest in company history. Same-store occupancy increased 330 bps YoY, RevPAR grew 5.2%, and expense growth was just 0.7% per unit. Flow-through margins hit 65% with 300 bps of YoY margin expansion. This is a very strong read-through for DOC's Janus Living senior housing portfolio, which reported +13.8% SS NOI growth in Q1 and is tracking above the top of DOC's +8–12% FY guidance range.
• Demand Backdrop — Positive: WELL highlighted that the wealthiest age cohort in history (Baby Boomers controlling ~$100 trillion of assets) is driving demand, affordability has improved as net worth growth outpaced rent growth, and capacity in the system continues to shrink as communities cross 90–95% occupancy thresholds. These structural tailwinds directly benefit DOC's Janus Living portfolio.
• Capital Allocation — Informative: WELL completed $6.2B of transactions in Q2 alone (96% off-market), raised its FY2026 normalized FFO guidance midpoint by $0.12 to $6.40/share, and announced a 15% dividend increase. The scale of WELL's investment activity at attractive yields (average ~6.6% year-one) confirms that senior housing transaction markets remain highly active and that institutional capital is aggressively pursuing the sector.
• Life Science — No Read-Through: WELL has no meaningful life science exposure; no commentary on lab demand.

Ventas (VTR) — Q2 2026 Earnings (Reported July 30, 2026)

Read-Through Relevance: VTR is a direct peer in both senior housing and life science/research (OMAR portfolio). Its research segment commentary is the most relevant lab read-through available.

• Senior Housing (SHOP) — Very Positive Read-Through for DOC: VTR reported U.S. SHOP NOI growth of 18% YoY with 360 bps of occupancy growth in Q2. Same-store SHOP NOI increased 16% YoY, one of the strongest quarterly growth rates in recent history. RevPAR grew 5% YoY, expense growth moderated to 5%, and NOI margins expanded 210 bps to 31%. VTR raised its FY2026 investment guidance from $3B to $4.5B, focused entirely on senior housing, and expects SHOP to reach 60% of its $60B enterprise by year-end. This is a strong read-through for DOC's Janus Living, confirming the sector-wide demand environment is exceptional.
• Life Science / Research (OMAR) — Cautious Read-Through for DOC: VTR's research segment experienced occupancy loss in Q2 due to a few tenants not renewing leases, resulting in a net impact of ~$900K YoY, which was in line with expectations. VTR noted this performance is anticipated to reflect the balance of the year. While the dollar impact is small for VTR, the pattern of non-renewals is consistent with the broader lab market headwinds DOC is navigating. However, VTR's research portfolio is much smaller than DOC's, limiting direct comparability.
• Supply Dynamics — Positive for Long-Term Lab Recovery: VTR highlighted that new starts for senior housing remain at record lows, with demand projected to substantially outrun supply. While this commentary is senior housing-specific, the same supply-constrained dynamic applies to lab real estate, where DOC management has noted supply is going to zero in core markets.
• Balance Sheet — Informative: VTR's net debt to EBITDA improved to 4.7x, the best leverage level in over a decade. VTR raised $4.2B of equity YTD and has $4.9B of liquidity. The strong capital markets access for healthcare REITs is a positive read-through for DOC's own capital recycling program and ability to fund the $1B acquisition target.

Healthcare Realty (HR) — Q2 2026 Earnings (Reported July 31, 2026)

Read-Through Relevance: HR is the purest outpatient medical office REIT peer — its Q2 results are the most direct read-through for DOC's Outpatient Medical segment.

• Outpatient Medical Leasing — Very Positive Read-Through for DOC: HR reported normalized FFO of $0.41/share and same-store cash NOI growth of 5.1% in Q2 2026, outperforming its own guidance. HR executed 323 leases totaling 1.5M sq ft (including 350K sq ft of new leasing), with cash re-leasing spreads of 4.8%, average escalators of 3%, and tenant retention of 88.5%. Occupancy reached nearly 93%, with 460K sq ft of signed-not-occupied leases providing visibility into H2 gains. This is a strong read-through for DOC's Outpatient Medical segment, which reported 5.4% cash re-leasing spreads and 91% occupancy in Q1.
• Sector Fundamentals — Positive: HR noted that medical outpatient completions as a percentage of inventory are hovering near all-time lows, while sector occupancy continues to reach record highs (sector-wide at ~93% for 20–25 consecutive quarters). The medical office transaction market remains vibrant, with institutional capital (including KKR via HR's JV) actively pursuing the sector at attractive yields (~7.5% going-in cash yield vs. ~6% implied cap rate). Increased health system M&A activity is driving stronger tenant credit and additional demand for outpatient space.
• Guidance Raised — Positive: HR raised its FY2026 normalized FFO guidance by $0.02 to $1.60/share at the midpoint (upper end raised to $1.66) and raised its same-store cash NOI outlook to 4.25–5.0% (up 50 bps at the bottom, 25 bps at the top). HR noted it is tracking ahead of schedule on its strategic plan's FFO range of $1.65–$1.85. This is a positive read-through for DOC's outpatient segment, suggesting the 2–3% SS NOI guidance may prove conservative.
• Inpatient-to-Outpatient Shift — Structural Positive: HR highlighted the continued push from inpatient to outpatient facilities, with health systems doing more procedures in outpatient settings due to higher margins. This structural demand driver benefits DOC's 50%+ outpatient medical portfolio and supports the long-term leasing spread and occupancy trajectory.

Peer Read-Through Summary Table

Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the Janus Living IPO completion in March, which unlocked a valuation premium for the senior housing portfolio at ~20 turns higher than DOC's own multiple. The Blackstone JV recap and Gateway leasing momentum are secondary positives; the Morgan Stanley downgrade is the key cautionary signal.

• March 2026 — Janus Living IPO Completed: Healthpeak completed the IPO of its senior housing business, Janus Living, in a "unique and creative transaction." Healthpeak retained 81.6% ownership (~$5.7B market value). The $240M of current-year FFO from the portfolio is now valued at a multiple ~20 turns higher than DOC itself. The IPO is expected to be earnings neutral in 2026 and accretive by ~$0.04/share once fully invested and stabilized. Implication: This is the single most important strategic development since Q4 2025 earnings — it unlocks hidden value and provides a template for further capital recycling.
• March 2026 — Blackstone JV Recap Closed at 6.1% Cap Rate: DOC closed a joint venture recap with Blackstone on a fully occupied outpatient portfolio at a 6.1% cash cap rate, raising $170M in proceeds. Management noted this is ~200 bps inside the implied cap rate in the stock price. Implication: Validates outpatient asset values and provides a template for future recaps; $700M+ of additional transactions are in progress.
• January 2026 — Gateway Campus Acquisition (South San Francisco): DOC completed the acquisition of the Gateway campus in South San Francisco for "a small fraction of replacement cost." As of Q1, 62K sq ft of signed leases and LOIs were in place, with 113K sq ft of active proposals and tours. Management stated they are "already ahead of schedule" on leasing. Implication: Upside to 2027–2028 earnings as lease-up progresses; signed rents at or above underwriting.
• April 2026 — $100M Share Buyback at >10% FFO Yield: DOC repurchased $100M of stock in April at an implied FFO yield of over 10%, which management cited as the primary driver of the FY2026 guidance raise. Implication: Signals management's view that the stock is undervalued; accretive to FFO/share.
• June 11, 2026 — Morgan Stanley Downgrade (Overweight → Equal-Weight, PT $20 → $22): Morgan Stanley analyst Richard Hill downgraded DOC from Overweight to Equal-Weight, citing increased lab tenant credit risk and weak Q2 leasing performance, while raising the price target from $20 to $22. The firm revised its CAGR forecast for FFOPS/AFFOPS to +1%/-1% for 2026–2027 (from +2%/+1%). Implication: Key cautionary signal from a major institutional voice; lab credit quality and Q2 leasing execution will be closely scrutinized on the earnings call.
• July 7, 2026 — Barclays Initiates Coverage (Equal-Weight, PT $23): Barclays initiated coverage of DOC with an Equal-Weight rating and a $23 price target. Implication: New institutional coverage adds visibility; $23 PT is above current consensus of ~$20–21, suggesting Barclays sees upside from current levels.
• May 13, 2026 — Robert W. Baird Raises PT ($19 → $21, Outperform): Baird raised its price target on DOC from $19 to $21 and maintained an Outperform rating following Q1 results. Implication: One of the more bullish sell-side voices; PT raise reflects confidence in the recovery narrative.
• July 15, 2026 — Wells Fargo Raises PT ($20 → $22, Equal-Weight): Wells Fargo raised its price target on DOC from $20 to $22 while maintaining an Equal-Weight rating. Implication: Consensus PT drift higher reflects improving sentiment, though the Hold-heavy rating distribution (63% Hold, 38% Buy) suggests the street is not yet fully convicted on the recovery.
• Q1 2026 — Lab Leasing Pipeline: 355K sq ft Under LOI (80% New, 75% on Vacant Space): As of Q1 earnings, DOC had 355K sq ft of lab leases under LOI, with ~80% being new leasing and ~75% on currently vacant space. Four deals greater than 50K sq ft were in the pipeline. South San Francisco continues to see the strongest active demand. Implication: Conversion of this pipeline is the key driver of the year-end occupancy target; any update on LOI-to-lease conversion will be closely watched.
• Q1 2026 — Alewife Mixed-Use Project Receives Preliminary Planning Approval: DOC received preliminary planning board approval for the Alewife mixed-use project. Entitlements are expected towards Q4 2026, with a potential groundbreaking of a residential building by Hines in 2027. Implication: Long-term value creation optionality; not a near-term earnings driver.

Insider Transaction Activity

Key Takeaway: Insider activity since Q1 2026 earnings is limited to a single open-market sale by the CDO and Head of Lab — a modest discretionary sale of ~$200K in value. The absence of open-market buying by insiders is notable given management's stated view that the stock is undervalued (implied by the $100M buyback at >10% FFO yield), though the small size and single transaction do not constitute a meaningful bearish signal.

Source: SEC Form 4 Filings Database (Insider Transaction Data). Window: May 6, 2026 – August 3, 2026. Only open-market buys (code P) and sells (code S) are included. No open-market purchases were filed by any DOC insider during this period. The sale by Scott Bohn (CDO and Head of Lab) is the only disclosed transaction; it is discretionary (no 10b5-1 plan indicated) but small in absolute dollar terms (~$215K estimated at ~$19.55/share on May 12). The fact that the Head of Lab sold shortly after Q1 earnings — when lab occupancy missed consensus — is worth noting, though the size is too small to draw strong conclusions. No other C-suite or director transactions were filed.

Analyst Consensus Summary (as of August 3, 2026): 16 analysts cover DOC; consensus rating is Hold (38% Buy, 63% Hold, 0% Sell). Consensus price target is approximately $20.62–$21.36, with recent targets ranging from $21 (Baird, Outperform) to $23 (Barclays, Equal-Weight). The stock closed at $21.84 on July 31, 2026, slightly above the consensus PT range, suggesting limited upside priced in at current levels absent a positive catalyst from Q2 results.